Back to top
more

IDEXX Laboratories (IDXX)

(Delayed Data from NSDQ)

$658.06 USD

658.06
564,509

+8.00 (1.23%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $658.67 +0.61 (0.09%) 4:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (145 out of 244)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Why IDEXX (IDXX) Could Be an Impressive Growth Stock

by Zacks Equity Research

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider IDEXX (IDXX).

Zacks Equity Research

Henry Schein (HSIC) Hits New 52-Week High: What's Driving It?

by Zacks Equity Research

Henry Schein (HSIC) is optimistic about maintaining robust sales of PPE and COVID-19-related products.

Zacks Equity Research

IDEXX (IDXX) Earnings Beat Estimates in Q1, '21 View Up

by Zacks Equity Research

IDEXX (IDXX) registers strong contribution from its CAG business in the first quarter despite pandemic-induced challenges.

Zacks Equity Research

Idexx Laboratories (IDXX) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Idexx (IDXX) delivered earnings and revenue surprises of 36.63% and 5.87%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Idexx Laboratories (IDXX) Stock Moves -0.66%: What You Should Know

by Zacks Equity Research

In the latest trading session, Idexx Laboratories (IDXX) closed at $548.99, marking a -0.66% move from the previous day.

Zacks Equity Research

What's in Store for IDEXX Laboratories (IDXX) in Q1 Earnings?

by Zacks Equity Research

IDEXX (IDXX) first-quarter top line is expected to have benefited from strength in CAG and LPD businesses.

Zacks Equity Research

Zimmer Biomet (ZBH) Enhances ZBEdge Portfolio With Latest Suite

by Zacks Equity Research

Zimmer Biomet's (ZBH) latest portfolio enhancement is aimed at improving patient outcome throughout the entire treatment process.

Zacks Equity Research

Omnicell's (OMCL) 2025 Roadmap Impressive, Pandemic Woe Stays

by Zacks Equity Research

Omnicell (OMCL) expands its autonomous pharmacy portfolio with the acquisition of PSG's 340B Link business.

Zacks Equity Research

Here's Why You Should Hold on to Medtronic (MDT) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Medtronic (MDT) on its slew of product launches and regulatory approvals.

Zacks Equity Research

Logitech, Harley-Davidson, Fulgent Genetics, Bio-Rad Laboratories and IDEXX Laboratories highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Logitech, Harley-Davidson, Fulgent Genetics, Bio-Rad Laboratories and IDEXX Laboratories highlighted as Zacks Bull and Bear of the Day

Urmimala Biswas headshot

COVID-19 Resurgence Accelerates Diagnostic Testing: 3 Top Picks

by Urmimala Biswas

We have narrowed down our search to the following stocks, FLGT, BIO and IDXX based on a favorable Zacks Rank and strong prospects for 2021.

Zacks Equity Research

Walgreens Boots (WBA) Q2 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Walgreens Boots' (WBA) fiscal second-quarter results reflect overall top-line improvement despite COVID-19-led business disruptions.

Zacks Equity Research

Reasons to Hold on to Syneos Health (SYNH) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Syneos Health (SYNH) on solid sequential recovery of its operating segments and strategic partnerships.

Zacks Equity Research

Here's Why You Should Hold on to Ecolab (ECL) Stock for Now

by Zacks Equity Research

Ecolab (ECL) continues to gain traction for a solid product portfolio and cost-efficiency program. However, segmental weakness is worrisome.

Zacks Equity Research

BD (BDX) Receives FDA EUA for Combination Rapid Antigen Test

by Zacks Equity Research

BD (BDX) gets FDA EUA for new rapid, antigen test, which can distinguish between COVID-19, influenza A and influenza B in a single test.

Zacks Equity Research

Zacks Industry Outlook Highlights: Natus Medical, IDEXX Laboratories, Hologic, Thermo Fisher Scientific and Abiomed

by Zacks Equity Research

Zacks Industry Outlook Highlights: Natus Medical, IDEXX Laboratories, Hologic, Thermo Fisher Scientific and Abiomed

Zacks Equity Research

Late-Breaking Data Supports Boston Scientific's (BSX) TheraSphere

by Zacks Equity Research

Boston Scientific's (BSX) TheraSphere is expected to be used as a safe and effective treatment option for numerous HCC patients worldwide on the back of positive trial results.

Zacks Equity Research

Here's Why You Should Retain Henry Schein (HSIC) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Henry Schein (HSIC) on robust sales of PPE and COVID-19-related products.

Zacks Equity Research

Here's Why You Should Retain Merit Medical (MMSI) Stock Now

by Zacks Equity Research

Merit Medical (MMSI) continues to gain traction on a solid product portfolio and strong international exposure. However, stiff competition is worrisome.

Zacks Equity Research

OPKO Health (OPK) BioReference Extends COVID-19 School Testing

by Zacks Equity Research

OPKO Health's (OPK) BioReference expands COVID-19 testing in schools to create a safer learning environment for students, teachers, staff and their families.

Urmimala Biswas headshot

3 Top Medical Instruments Stocks to Beat COVID-19 Resurgence Crisis

by Urmimala Biswas

Despite the severe challenges posed by the COVID-19 pandemic, higher demand for telemedicine, digital influence and AI is likely to lend support to the Zacks Medical - Instruments industry. NTUS, IDXX and HOLX are well positioned to gain.

Zacks Equity Research

AmerisourceBergen (ABC) Hits New 52-Week High: What's Driving It?

by Zacks Equity Research

AmerisourceBergen (ABC) is optimistic about maintaining a robust segmental performance amid the pandemic-led business disruptions.

Zacks Equity Research

Here's Why You Should Retain PerkinElmer (PKI) Stock Now

by Zacks Equity Research

PerkinElmer (PKI) continues to gain traction for solid product portfolio and improving margins. However, forex is a woe

Debanjana Dey headshot

5 MedTech Growth Stocks Gaining Ground in 2021 Amid Pandemic

by Debanjana Dey

Here are a few MedTech stocks, ABT, HOLX, HRC, IDXX, LMAT, which have held their ground amid the pandemic and can turn out to be wise investment choices for 2021.

Zacks Equity Research

Zacks.com featured highlights include: Toll Brothers, Goldman Sachs, Owens Corning, CBRE Group and IDEXX Laboratories

by Zacks Equity Research

Zacks.com featured highlights include: Toll Brothers, Goldman Sachs, Owens Corning, CBRE Group and IDEXX Laboratories